Welcome to our dedicated page for Seelos Therapeutics news (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on Seelos Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seelos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seelos Therapeutics's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Seelos Therapeutics (Nasdaq: SEEL) announced the initiation of its Expanded Access Program (EAP) for patients with Amyotrophic Lateral Sclerosis (ALS) who do not qualify for existing clinical trials. Funded by a NINDS grant under the ACT for ALS, the program aims to enroll 70 patients over 24 weeks to evaluate SLS-005. This investigational treatment is designed to stabilize proteins and activate autophagy. The CEO expressed gratitude for community support and emphasized the importance of the EAP for ALS patients lacking other therapy options. The ongoing Phase II/III study on the HEALEY ALS Platform will run concurrently.
Seelos Therapeutics (Nasdaq: SEEL) provided an update on March 29, 2023, focusing on its clinical programs. The company is temporarily pausing patient enrollment in the SLS-005-302 study for spinocerebellar ataxia type 3 (SCA3) due to financial considerations, although current participants will continue in the study. Seelos aims to concentrate resources on the SLS-002 study for Acute Suicidal Ideation and Behavior with expected data readout by Q3 2023, and the SLS-005 study for ALS data in late 2023. Seelos' corporate structure allows for strategic flexibility while extending its cash runway for upcoming data readouts.
Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced a registered direct offering of 12,059,298 shares of common stock and warrants for 26,750,000 shares at a price of
Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced its participation in the 43rd Annual Cowen Health Care Conference happening in Boston, Massachusetts from March 6-8, 2023. CEO Raj Mehra and senior management will host meetings during the event. Seelos is focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Acute Suicidal Ideation in Major Depressive Disorder and various neurodegenerative diseases including ALS and Huntington’s disease. For more details, visit their website.